The invention relates to at least one molecular target for healing or treating wounds and in particular chronic human wounds. The molecular target is PTPRK or a protein 50% homologous therewith and which retains the same activity as PTPRK protein. Further the invention concerns a novel therapeutic for treating said wounds and a novel gene therapy approach involving said molecular target for treating said wounds.